NyxoahNYXH +2.70%60 Days Payable is 136.21 as of Mar. 2026, which is 83% below its 10-year median of 800.18. GuruFocus rates NYXH with a GF Score™ of 60/100 and a GF Value™ of $22.17 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 796 Medical Devices & Instruments companies, Nyxoah ranks better than 87.06% on this metric.
Nyxoah's average Accounts Payable for the
three
months ended in Mar. 2026 was $4.72 Mil. Nyxoah's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $3.16 Mil.
Hence, Nyxoah's Days Payable for the
three
months ended in Mar. 2026 was 136.21.
The historical rank and industry rank for Nyxoah's Days Payable or its related term are showing as below:
NYXH'
s Days Payable Range Over the Past 10 Years
Min: 245.54 Med: 800.18 Max: 12099.75
Current: 245.54
During the past 9 years, Nyxoah's highest Days Payable was 12099.75. The lowest was 245.54. And the median was 800.18.
NYXH's Days Payable is ranked better than 87.06% of 796
companies
in the Medical Devices & Instruments industry
Industry Median: 67.97
vs NYXH: 245.54
Nyxoah's Days Payable
declined
from Mar. 2025 (908.65) to Mar. 2026 (136.21).
It may suggest that Nyxoahaccelerated paying its suppliers.
Nyxoah Days Payable Related Terms
Nyxoah Days Payable Historical Data
* Premium members only.
The historical data trend for Nyxoah's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Nyxoah's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nyxoah Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nyxoah's Days Payable distribution charts can be found below:
* The bar in red indicates where Nyxoah's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Nyxoah's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nyxoah (NYXH) has a Days Payable of 136.21 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Nyxoah and its competitors. This is 83% below median its historical median of 800.18. Over the past decade, Nyxoah's Days Payable has ranged from 245.54 to 12,099.75. According to the industry distribution chart, Nyxoah ranks #103 out of 796 companies in the Medical Devices & Instruments industry, placing it in the top 12.9%.
Is Nyxoah's Days Payable too high?
Nyxoah's current Days Payable of 136.21 is 83% below median its 10-year median of 800.18. Over the past 10 years, this metric has ranged from a low of 245.54 to a high of 12,099.75. The Medical Devices & Instruments industry median Days Payable is 67.97. Nyxoah's value of 136.21 is 100.4% above this industry median. Based on the distribution chart, Nyxoah ranks #103 out of 796 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Nyxoah has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nyxoah's Days Payable compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Nyxoah ranks #103 out of 796 companies for Days Payable. This places Nyxoah in the top 13% of its industry — outperforming the majority of peers. The industry median Days Payable is 67.97. Nyxoah's value of 136.21 is 100.4% above this benchmark. Historically, Nyxoah's own Days Payable has ranged from 245.54 to 12,099.75 over the past decade. While the company's 10-year median is 800.18 vs. the industry median of 67.97, Nyxoah has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.97, based on 796 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nyxoah's current Days Payable of 136.21 is 100.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Nyxoah and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nyxoah's current Days Payable is 136.21, which is 83% below median its own 10-year median of 800.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nyxoah stock overvalued right now?
Based on GuruFocus' analysis, Nyxoah (NYXH) is currently considered Possible Value Trap. The stock's GF Value™ is $22.17, compared to a current price of $1.72 — trading 92.2% below its estimated fair value. The current Days Payable is 136.21, which is 83% below median its 10-year median of 800.18 and 100.4% above the Medical Devices & Instruments industry median of 67.97. Nyxoah's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Nyxoah (NYXH), the current Days Payable is 136.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nyxoah (NYXH) Overvalued in 2026?
Based on GuruFocus' analysis, Nyxoah stock appears to be undervalued.
The current stock price of $1.72 is trading 92.2% below its estimated GF Value™ of $22.17.
GuruFocus considers Nyxoah to be Possible Value Trap.
Key valuation signals for NYXH:
Days Payable: 136.21 (83% below median its 10-year median of 800.18)
GF Value™: $22.17 vs. price of $1.72 (92.2% below fair value)
Industry Position: 100.4% above the Medical Devices & Instruments median (#103 of 796)
No single metric tells the full story. See the NYXH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
60GF Score
Get the complete analysis for NYXH
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NYXH has been successfully added to your 
